180 related articles for article (PubMed ID: 15730857)
21. Prevention of diabetes in NOD mice at a late stage by targeting OX40/OX40 ligand interactions.
Pakala SV; Bansal-Pakala P; Halteman BS; Croft M
Eur J Immunol; 2004 Nov; 34(11):3039-46. PubMed ID: 15368274
[TBL] [Abstract][Full Text] [Related]
22. OX40 (CD134) and OX40 ligand interaction plays an adjuvant role during in vivo Th2 responses.
Ishii N; Ndhlovu LC; Murata K; Sato T; Kamanaka M; Sugamura K
Eur J Immunol; 2003 Sep; 33(9):2372-81. PubMed ID: 12938213
[TBL] [Abstract][Full Text] [Related]
23. Expression of OX40 ligand in microglia activated by IFN-gamma sustains a protective CD4+ T-cell response in vitro.
Wang Y; Li M; Song M; Xu X; Xiong J; Yang X; Tan J; Bai Y
Cell Immunol; 2008 Feb; 251(2):86-92. PubMed ID: 18485335
[TBL] [Abstract][Full Text] [Related]
24. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
25. Expression and function of the OX40/OX40L costimulatory pair during herpes stromal keratitis.
Lepisto AJ; Xu M; Yagita H; Weinberg AD; Hendricks RL
J Leukoc Biol; 2007 Mar; 81(3):766-74. PubMed ID: 17185358
[TBL] [Abstract][Full Text] [Related]
26. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
[TBL] [Abstract][Full Text] [Related]
27. Rapid induction of OX40 ligand on primary T cells activated under DNA-damaging conditions.
Kondo K; Okuma K; Tanaka R; Matsuzaki G; Ansari AA; Tanaka Y
Hum Immunol; 2008 Sep; 69(9):533-42. PubMed ID: 18718855
[TBL] [Abstract][Full Text] [Related]
28. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
[TBL] [Abstract][Full Text] [Related]
29. The crystal structure of the costimulatory OX40-OX40L complex.
Compaan DM; Hymowitz SG
Structure; 2006 Aug; 14(8):1321-30. PubMed ID: 16905106
[TBL] [Abstract][Full Text] [Related]
30. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
Ruby CE; Redmond WL; Haley D; Weinberg AD
Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
[TBL] [Abstract][Full Text] [Related]
31. OX40 ligand shuts down IL-10-producing regulatory T cells.
Ito T; Wang YH; Duramad O; Hanabuchi S; Perng OA; Gilliet M; Qin FX; Liu YJ
Proc Natl Acad Sci U S A; 2006 Aug; 103(35):13138-43. PubMed ID: 16924108
[TBL] [Abstract][Full Text] [Related]
32. Regulation of OX40 gene expression in graft-versus-host disease.
Miura Y; Thoburn CJ; Bright EC; Arai S; Hess AD
Transplant Proc; 2005; 37(1):57-61. PubMed ID: 15808546
[TBL] [Abstract][Full Text] [Related]
33. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice.
van Wanrooij EJ; van Puijvelde GH; de Vos P; Yagita H; van Berkel TJ; Kuiper J
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):204-10. PubMed ID: 17068285
[TBL] [Abstract][Full Text] [Related]
34. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
35. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis.
Akiba H; Miyahira Y; Atsuta M; Takeda K; Nohara C; Futagawa T; Matsuda H; Aoki T; Yagita H; Okumura K
J Exp Med; 2000 Jan; 191(2):375-80. PubMed ID: 10637281
[TBL] [Abstract][Full Text] [Related]
36. Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA.
Mestas J; Crampton SP; Hori T; Hughes CC
Int Immunol; 2005 Jun; 17(6):737-47. PubMed ID: 15908450
[TBL] [Abstract][Full Text] [Related]
37. Costimulation through OX40 is crucial for induction of an alloreactive human T-cell response.
Ukyo N; Hori T; Yanagita S; Ishikawa T; Uchiyama T
Immunology; 2003 Jun; 109(2):226-31. PubMed ID: 12757617
[TBL] [Abstract][Full Text] [Related]
38. Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signalling: enhancement of IgG production of B cells and promotion of maturation of DCs.
Wang Q; Chen Y; Ge Y; Sun J; Shi Q; Ju S; Dai J; Yu G; Zhang X
Tissue Antigens; 2004 Nov; 64(5):566-74. PubMed ID: 15496199
[TBL] [Abstract][Full Text] [Related]
39. Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation.
Wang HC; Klein JR
J Immunol; 2001 Dec; 167(12):6717-23. PubMed ID: 11739485
[TBL] [Abstract][Full Text] [Related]
40. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
Ho RL; Maccubbin DL; Ujházy P; Zaleskis G; Eppolito C; Mihich E; Ehrke MJ
Oncol Res; 1993; 5(9):363-72. PubMed ID: 8038457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
